Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings

Nathan Ford, Janice Lee, Isabelle Andrieux-Meyer, Alexandra Calmy, Nathan Ford, Janice Lee, Isabelle Andrieux-Meyer, Alexandra Calmy

Abstract

The vast majority of people living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome reside in the developing world, in settings characterized by limited health budgets, critical shortages of doctors, limited laboratory monitoring, a substantial burden of HIV in children, and high rates of coinfection, in particular tuberculosis. Therefore, the extent to which new antiretrovirals will contribute to improvements in the management of HIV globally will depend to a large extent on their affordability, ease of use, low toxicity profile, availability as pediatric formulations, and compatibility with tuberculosis and other common drugs. We undertook a systematic review of the available evidence regarding drug interactions, and the efficacy and safety of rilpivirine (also known as TMC-278), and assessed our findings in view of the needs and constraints of resource-limited settings. The main pharmacokinetic interactions relevant to HIV management reported to date include reduced bioavailability of rilpivirine when coadministered with rifampicin, rifabutin or acid suppressing agents, and reduced bioavailability of ketoconazole. Potential recommendations for dose adjustment to compensate for these interactions have not been elaborated. Trials comparing rilpivirine and efavirenz found similar outcomes up to 96 weeks in intent-to-treat analysis; failure of rilpivirine was mainly virological, whereas failure among those exposed to efavirenz was mainly related to the occurrence of adverse events. Around half of the patients who fail rilpivirine develop non-nucleoside reverse transcriptase inhibitor resistance mutations. The incidence of Grade 2-4 events was lower for rilpivirine compared with efavirenz. Grade 3-4 adverse events potentially related to the drugs were infrequent and statistically similar for both drugs. No dose-response relationship was observed for efficacy or safety, and the lowest dose (25 mg) was selected for further clinical development. The potential low cost and dose of the active pharmaceutical ingredient means that rilpivirine can potentially be manufactured at a low price. Moreover, its long half-life suggests the potential for monthly dosing via nonoral routes, with promising early results from studies of a long-acting injectable formulation. These characteristics make rilpivirine an attractive drug for resource-limited settings. Future research should assess the potential to improve robustness and assess the clinical significance of interaction with antituberculosis drugs.

Keywords: TMC-278; efficacy; pharmacology; rilpivirine; safety.

References

    1. Hogg R, Lima V, Sterne JA, et al. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–299.
    1. Mills E, Bakanda C, Chan K, et al. for the TASO-CAN group. Life expectancy of individuals on combination antiretroviral therapy in Uganda: a cohort analysis of more than 23,000 patients. Abstract TUPE0212, presented at the XVIII International AIDS Conference; July 18–23, 2010; Vienna, Austria.
    1. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.
    1. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: A systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24(10):1461–1470.
    1. Garvey L, Winston A. Rilpivirine: A novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs. 2009;18(7):1035–1041.
    1. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother. 2010;44(1):157–165.
    1. Hughes CA, Robinson L, Tseng A, MacArthur RD. New antiretroviral drugs: A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother. 2009;10(15):244–266.
    1. Miller CD, Crain J, Tran B, Patel N. Rilpivirine: A new addition to the anti-HIV-1 armamentarium. Drugs Today (Barc) 2011;47(1):5–15.
    1. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects. AIDS. 2006;20(13):1721–1726.
    1. Arastéh K, Rieger A, Yeni P, et al. Short-term randomized proof-of- principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antiviral Ther. 2009;14(5):713–722.
    1. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: Week 96 results of a phase IIb randomized trial. AIDS. 2010;24(1):55–65.
    1. Van’t Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010;54(5):2042–2050.
    1. Baert L, van’t Klooster G, Dries W, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm. 2009;72(3):502–508.
    1. Van Gyseghem E, Pendela M, Baert L, et al. Powder for reconstitution of the anti-HIV-1 drug TMC278 – formulation development, stability and animal studies. Eur J Pharm Biopharm. 2008;70(3):853–860.
    1. Cohen C, Molina JM, Cahn P, et al. Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients. Abstract 048, presented at the Tenth International Congress on Drug Therapy in HIV Infection; November 7–11, 2010; Glasgow, Scotland.
    1. Rimsky L, Eron J, Clotet B, et al. Characterization of the resistance profile of TMC278: 48-week analysis of the phase 3 studies ECHO and THRIVE. Abstract H-1810, presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2010; Boston, MA.
    1. Verloes R, van’t Klooster G, Baert L, et al. TMC278 long acting – a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers. Abstract TUPE0042, presented at the XVII International AIDS Conference; August 3–8, 2008; Mexico City, MX.
    1. Crauwels H, van Heeswijk R, Kestens D, et al. The pharmacokinetic (PK) interaction between rifabutin and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). Abstract TUPE0080, presented at the XVIIth International AIDS Conference; August 3–8, 2008; Mexico City, MX.
    1. Crauwels H, van Heeswijk R, McNeeley D, et al. Relative bioavailability of a concept paediatric formulation of TMC278, an investigational NNRTI. Abstract TUPE0158, presented at the XVIIIth International AIDS Conference; July 18–23, 2010; Vienna, Austria.
    1. Hoetelmans R, Kestens D, Marien K, et al. Effect of food and multiple dose pharmacokinetics of TMC278 as an oral tablet formulation Abstract TuPe31B10. presented at the Third International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24–27, 2005; Rio de Janeiro, Brazil.
    1. De Béthune M-P, Andries K, Azijin H, et al. TMC278, a new potent NNRTI, with an increased barrier to resistance and favourable pharmacokinetic profile. Poster 556, presented at the 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston, MA.
    1. Van Heeswijk R, Hoetelmans RMW, Kestens D, et al. The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). Poster 74, presented at the Seventh International Workshop of Clinical Pharmacology; April 20–22, 2006; Lisbon, Portugal.
    1. Chamie G, Luetkemeyer A, Charlebois E, Havlir DV. Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis. 15;50(Suppl 3):S245–254.
    1. Van Heeswijk R, Hoetelmans RMW, Kestens D, et al. The pharmacokinetic interaction between TMC 278, a next generation NNRTI, and once-daily darunavir/ritonavir in HIV negative volunteers. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2007; Chicago, IL.
    1. Crauwels H, van Heeswijk R, Vandevoorde A, et al. Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone. Abstract WEPE0089, presented at the XVIII International AIDS Conference; July 18–23, 2010; Vienna, Austria.
    1. Van Heeswijk RPG, Hoetelmans RMW, Aharchi F, et al. The pharmacokinetic interaction between atorvastatin and TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor, in HIV-negative volunteers. Presented at the 11th European AIDS Conference; October 24–27, 2007; Madrid, Spain.
    1. Crauwels H, van Heeswijk R, Cornelis L, et al. Pharmacokinetic interaction study between TMC278, an NNRTI, and the contraceptives norethindrone plus ethinylestradiol. Presented at the 12th European AIDS Conference; November 11–14, 2009; Cologne, Germany.
    1. Crauwels H, van Heeswijk R, Stevens M, et al. TMC278, a next-generation NNRTI, does not alter the pharmacokinetics of sildenafil. Abstract presented at the 10th International Workshop on Clinical Pharmacology of HIV; April 15–17, 2009; Amsterdam, the Netherlands.
    1. Santoscoy M, Cahn P, Gonsalez C, et al. TMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naïve patients: 96-week results of study C204. Abstract TUAB0103, presented at the XVIIth International Aids Conference; August 3–8, 2008; Mexico City, MX.
    1. Mathias AMM, Wei X, Dave A, et al. Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DF. Abstract LBPE17, presented at the XVIII International AIDS Conference; July 18–23, 2010; Vienna, Austria.
    1. Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[ 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) J Med Chem. 2005;48(6):1901–1909.
    1. Crauwels HM, van Heeswijk R, Bollen A, et al. The effect of different types of food on the bioavailability of TMC278, an investigational NNRTI. Poster presented at the Ninth International Workshop on Pharmacology of HIV Therapy; April 7–9, 2008; New Orleans, LA.
    1. Hoetelmans R, Kestens D, Stevens M, et al. Pharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir fumarate (TDF) in healthy volunteers. Poster 18, presented at the Sixth International Workshop on Clinical Pharmacology of HIV Therapy; April 28–30, 2005; Quebec City, QC.
    1. Van Heeswijk R, Hoetelmans RM, Kestens D, et al. The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy HIV-negative subjects. Abstract TUPE0087, presented at the XVI International AIDS Conference; August 13–18, 2006; Toronto, ON.
    1. Van Heswijk R, Hoetelmans RM, Kestens D, et al. The pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteers. Abstract TUPDB01, presented at the Fourth International AIDS Society Conference on HIV Pathogenesis; July 22–25, 2007; Sydney, Australia.
    1. Vanveggel S, Buelens A, Crauwels H, et al. TMC278 25 mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers. Abstract PE7.1/2, presented at the 12th European AIDS Conference; November 11–14, 2009; Cologne, Germany.
    1. Desmidt M, Willems B, Dom P, et al. Absence of a teratogenic potential from a novel next generation NNRTI, TMC278. Abstract PE7.1/4 presented at 12th European AIDS Conference; November 11–14, 2009; Cologne, Germany.
    1. Pinheiro E, Vasan A, Kim JY, et al. Examining the production costs of antiretroviral drugs. AIDS. 2006;20(13):1745–1752.
    1. Campaign for Essential Medicines. Untangling the Web of Antiretroviral Price Reduction. 13th ed. Geneva, Switzerland: Medecins Sans Frontieres; 2010. [Accessed March 4, 2011]. Available at: .
    1. Johnson & Johnson. Tibotec signs multiple agreements with generic manufacturers to provide access to new HIV treatment. [Accessed March 30, 2011]. Available at: .
    1. World Health Organization. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report. Geneva, Switzerland: WHO/UNAIDS/UNICEF; 2009.
    1. World Health Organization. Updated List of Missing Drug Formulations for HIV Treatment to be Reviewed by the WHO 18th Expert Committee on the Selection and Use of Essential Medicines. [Accessed March 30, 2011]. Available at: .
    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–2599.
    1. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of bio-medical data from the Phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among US men who have sex with men (MSM). Abstract FRLBC102, presented at the XVIII International AIDS Conference; July 18–23, 2010; Vienna, Austria.
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–1174.
    1. Gostin LO, Kim SC. Ethical allocation of preexposure HIV prophylaxis. JAMA. 2011;305(2):191–192.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel